#Canada #Calgary #Innocan Pharma #Tamar Innovest #Debenture

Innocan Pharma's Strategic Debenture Offering

Innocan Pharma Corporation, a promising player in the pharmaceutical sector, has recently announced a strategic financial move that could bolster its growth trajectory. The company, trading under the symbols CSE: INNO, FSE: IP4, and OTC: INNPF, is preparing to issue a debenture to its largest shareholder, Tamar Innovest Ltd. This move comes as Innocan aims to secure gross proceeds of $450,000, which will substantially contribute to its working capital and other corporate initiatives.

Details of the Debenture

The debenture being offered will come with an interest rate of 10% per annum and will mature in 12 months from the date of issuance, or upon the completion of a previous public offering in the United States. This flexible timeline allows Innocan to utilize the funds raised for various organizational needs, including the costs associated with its anticipated NYSE listing.

Iris Bincovich, the CEO of Innocan, expressed optimism about the deal, stating, "We are delighted to receive an additional investment from our largest shareholder, Tamar Innovest." This statement underscores the importance of Tamar Innovest to Innocan, as they already hold a 17% stake in the company, indicating a robust level of confidence in Innocan's potential.

Implications of the Deal

This debenture issuance qualifies as a "related party transaction" under Multilateral Instrument 61-101, which is designed to protect minority shareholders in special transactions. Because Tamar Innovest is managed by Ralph Bossino, a director at Innocan, this classification ensures transparency and regulatory compliance. In fact, Innocan intends to rely on exemptions from certain requirements outlined in the instrument, given that the transaction’s fair value does not exceed 25% of the company's market capitalization.

The independent directors of the company have reviewed and approved this offering, further consolidating its legitimacy.

Innocan's Growth Vision

Innocan Pharma stands out not just for its financial maneuvers but also for its innovative approach in the pharmaceutical and wellness industries. The company has pioneered a CBD-loaded liposome drug delivery platform, designed to administer precise doses of synthetic CBD for effective non-opioid pain management. Furthermore, Innocan has diversified into the wellness sector, developing high-performance self-care and beauty products aimed at enhancing healthy lifestyles. Through its 60% owned subsidiary, BI Sky Global Ltd., the company is also keen on enhancing its online sales strategy.

In light of recent market trends, Innocan’s plans to expand further into the U.S. market highlights a strategic alignment with investors seeking robust growth in the pharmacological space. The significant investment from Tamar Innovest signifies a continued commitment to supporting Innocan's future endeavors.

Conclusion

As Innocan Pharma moves forward with this offering, both the company and its shareholders anticipate exciting developments ahead. With the planned utilization of the new capital aimed at supporting working capital needs and listing costs, Innocan is poised for potential growth that could benefit not only its investors but also the wider community looking for innovative health solutions.

The recent announcement has positioned Innocan as a significant player in the evolving market, demonstrating the potential for innovative pharmaceutical solutions, coupled with an agile investment strategy. With the support of major stakeholders like Tamar Innovest, Innocan is ready to tackle the challenges of the pharmaceutical landscape head-on.

For more information, visit Innocan Pharma's website.